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Neurodegeneration and synaptic dysfunction observed in Alzheimer’s disease (AD) have been associated
with progressive decrease in neuronal activity. Here, we investigated the effects of Notoginsenoside R1
(NTR1), a major saponin isolated from Panax notoginseng, on neuronal excitability and assessed the
beneficial effects of NTR1 on synaptic and memory deficits under the Ab-enriched conditions in vivo and in
vitro. We assessed the effects of NTR1 on neuronal excitability, membrane ion channel activity, and synaptic
plasticity in acute hippocampal slices by combining electrophysiological extracellular and intracellular
recording techniques. We found that NTR1 increased the membrane excitability of CA1 pyramidal neurons
in hippocampal slices by lowering the spike threshold possibly through a mechanism involving in the
inhibition of voltage-gated K1 currents. In addition, NTR1 reversed Ab1-42 oligomers-induced
impairments in long term potentiation (LTP). Reducing spontaneous firing activity with 10 nM
tetrodotoxin (TTX) abolished the protective effect of NTR1 against Ab-induced LTP impairment. Finally,
oral administration of NTR1 improved the learning performance of the APP/PS1 mouse model of AD. Our
work reveals a novel mechanism involving in modulation of cell strength, which contributes to the
protective effects of NTR1 against Ab neurotoxicity.
A
lzheimer’s disease (AD) is the most common form of dementia worldwide. It is characterized by the
presence of extracellular deposits of amyloid protein in senile plaques, and intracellular deposits of tau
protein in neurofibrillary tangles. A key feature of the disease is represented by the progressive synaptic
dismantling, impairment of neurotransmission and deficiency of neuronal network connections [see review1 for
detail]. Therefore, AD has been recognized as a synaptopathy2. Because of the synaptic failure hypothesis, studies
have frequently concentrated on analysis of synaptic function and plasticity; most of these studies have been
performed in hippocampus and cerebral cortex. By contrast, there is much less information concerning the
intrinsic properties of neurons following b-amyloid (Ab) peptides elevation or in AD brain3. Recent studies have
uncovered significant alterations at the level of intrinsic excitability of single neurons in AD mouse models4–6 or
upon exposure to Ab7,8.
A reduction of intrinsic neuronal excitability has been found in the cerebellar cortex of APP/PS1 mice, in
mouse dentate gyrus after application of synthetic Ab1-42 oligomers7, and in hippocampal CA1 pyramidal
neurons of 5XFAD mice3. In fact, AD patients have decreased neuronal activity in brain9–11. Furthermore, a
decrease in neuronal activity was observed in 29% of cortical neurons in APP/PS1 mice. Clusters of hyperactive
neurons were found exclusively near b-amyloid plaques, possibly due to a compensatory mechanism, aimed at re-
establishing the synaptic connectivity altered by the synaptic loss12. Abnormal neuronal excitability contributes to
the deficits in synaptic connectivity and hippocampal-based memory performance6,9. Therefore, modulation of
the neuronal excitability represents a potential strategy for preventing the impairments of synaptic function and
memory in AD brain. In support of this hypothesis, rotigotine, a dopamine agonist with high affinity for D3 and
D2 receptors increased cortical excitability and restored central cholinergic transmission in AD patients13. In
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another report, levetiracetam, an antiepileptic drug, reduced abnor-
mal spike activity and reversed synaptic dysfunction and deficits in
learning and memory in human amyloid precursor protein trans-
genic mice14. In addition, dietary omega-3 was found to improve
learning performance of diabetic rats by upregulation of the excit-
ability of CA1 pyramidal neurons15.
Panax notoginseng (Sanqi), a famous traditional Chinese herb
medicine, has a long history of use in East Asian countries for the
treatment of cardiovascular disease16,17. Notoginsenoside R1 (NTR1),
chemically named C47H80O18 (Fig. 1), a major ingredient isolated
from Panax notoginseng roots18, is known to possess anti-inflammat-
ory, anti-oxidative and anti-ischemia-reperfusion injury prop-
erties19–21. NTR1 is specifically distributed in Panax notoginseng,
unlike other ginsenosides such as ginsenoside R1, Rg1, R3, etc.,
which are distributed in both Panax notoginseng and Panax ginseng.
NTR1 has the same chemical structure as ginsenosides such as Rg1,
Rb1, Rg2, and Rg3, a common four-ring hydrophobic steroid-like
structure attached with sugar moieties22. Recent studies have shown
that ginsenosides have multifaceted neuroprotective effects in AD
and related models both in vitro and in vivo. For example,
Ginsenoside Rb1, Rg1, and Rg3 displayed protective effects against
Ab production and aggregation through mechanisms possibly
including reduction of APP expression, inhibition on b-secretase
activity as well as stimulation of a-secretase activity23–25. In addition,
Rg1and Rd prevented Ab-induced neurotoxicity such as mitochon-
drial dysfunction, tau hyperphosphorylation as well as neuronal
death26–28. Furthermore, ginsenosides remarkably improved cognit-
ive performance of AD patients and rodent models29–31. In contrast
to the defined neuroprotective effects of ginsenosides, whether noto-
ginsenoside R1 has neuroprotective effects and its mechanism of
action remain elusive. Here, we investigated the modulation by
NTR1of intrinsic excitability of hippocampal pyramidal neurons
and the putative neuroprotective effects of NTR1 against Ab1-42
oligomers-induced synaptic dysfunction and memory deficits in
primary cultured hippocampal neurons, in acute brain slice, and in
a mouse model of AD. Our study reveals that NTR1 prevents Ab-
induced synaptic dysfunction and improves hippocampal-based
memory performance in an AD mouse model through a possible
mechanism involved in the modulation of neuronal excitability.
Results
NTR1 increases membrane excitability of hippocampal CA1
pyramidal neurons. Since neuronal excitability has been associated
with synaptic plasticity, learning and memory32 and a disturbance in
equilibrium between silent and hyperactive neurons has been shown
in AD mouse brain12, we investigated the effects of NTR1 onto
intrinsic excitability of pyramidal neurons in the hippocampal CA1
region, an area critically involved in memory formation. In coronal
brain slices from mice of 2–3 months of age, spontaneous action
potential (sAPs) of hippocampal CA1 pyramidal neurons were
recorded without intermittency using the whole cell patch clamp
technique. NTR1 at a concentration of 10 mM was added to the
perfusion system. After NTR1 perfusion for 20 min, NTR1 was
washed out by switching the bath solution to normal ACSF. The
spontaneous firing rate of pyramidal neurons was obviously
increased after 10 mM NTR1 application compared with time-
matched control (vehicle) (Fig. 2a, b). Washout for 20 min
abolished the effect of NTR1 on firing (Fig. 2a, b). The whole-cell
recordings were performed continuously during vehicle or NTR1
perfusion procedure and firing frequency was measured at 1 min
interval. NTR1 did not affect the resting membrane potential or the
amplitude of sAPs (Fig. 2c), which indicated that NTR1 increased
membrane excitability of hippocampal neurons without
depolarization of cell membrane.
NTR1 decreases the threshold for the action potential appearance.
Using current-clamp configuration, evoked action potentials (eAPs)
were elicited through depolarizing current injection ranging from
250 pA to 190 pA in hippocampal pyramidal neurons (Fig. 3a).
Evoked by a current of 10 pA and 30 pA amplitudes, the firing
frequency of neurons was significantly (p 5 0.014 for 10 pA and p
5 0.028 for 30 pA, n512) increased after NTR1 application (Fig. 3b).
Before NTR1 application, only 16.7% neurons (n512) were able to
elicit eAPs with 10 pA current injection. But after NTR1 treatment,
83.3% neurons displayed eAPs with 10 pA current injection (Fig. 3c).
The delivery of 30 pA current elicited eAPs in 83.3% neurons in the
absence of NTR1, while all neurons (n512) showed eAPs in the pre-
sence of NTR1 (Fig. 3d). Consistent with spontaneous firing, the effect
of NTR1 on eAPs generation could be also abolished by NTR1
washout. In addition, there is no significant difference in maximum
firing rate evoked by 90 pA current injection after NTR1 application.
These results indicate that NTR1 reversibly increases neuronal
excitability, possibly due to a reduction of spike threshold.
NTR1 decreases spike threshold possibly through inhibiting
sustained potassium currents. Spike threshold was next measured
directly using the peak of the derivative of the spontaneous action
potential (Fig. 4a). NTR1 significantly and reversibly decreased AP
threshold (Fig. 4b, p 5 0.0026, n59 cells). An efflux of potassium
during single action potential can hyperpolarize the cell and thus
inhibit threshold from being reached. Thus, we next determined
the effect of NTR1 on voltage-dependent K1 currents. Voltage-
activated K1 currents were recorded as shown on Fig. 4d. The
membrane was held at 270 mV, and a 300 ms voltage step was
applied up to a value of 150 mV. NTR1 treatment significantly,
but reversibly, decreased the sustained K1 currents (Fig. 4e, p 5
0.018, n 5 7), which were measured at the end of the 300 ms pulse.
Fast afterhyperpolarization (AHP) is known to be involved in
delaying the subsequent firing of action potentials4. Thus, we inves-
tigated the effects of NTR1 on AHP amplitude, which may interpret
the rare effect of NTR1 on maximum firing rate. AHP amplitude was
slightly higher after NTR1 perfusion (21.94 6 0.32 mV for NTR1
versus 21.69 6 0.29 mV for baseline and 21.68 6 0.14 mV for
20 min washout, n59 cells, Fig. 4c; representative traces are shown
in Fig. 4a). This finding is in the same direction as the effect of NTR1
on the maximum rate of firing. These findings suggest that inhibition
of voltage-dependent K1 current channel by NTR1 may be respons-
ible for the increase in excitability of the hippocampal neurons.
Effect of NTR1 is major at a cellular level. The increase in
spontaneous firing may be due to the alternation of presynapticFigure 1 | Chemical structure of notoginsenoside R1 (NTR1).
www.nature.com/scientificreports
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transmission or the neuronal excitability, or both. To address this
question, we recorded the spontaneous miniature excitatory
postsynaptic currents (mEPSC), which can reflect any changes in
presynaptic neurotransmitter release and postsynaptic receptor
activity and thus reflect the network changes33. mEPSCs were
recorded in the presence of 100 mM picrotoxin and 0.5 mM TTX,
which can exclude the effects of NTR1 on postsynaptic neuron
properties but leave the synaptic response. No significance
Figure 2 | NTR1 enhances the excitability of hippocampal CA1 pyramidal neurons in acute brain slices. (a). Changes in spontaneous action potentials
(sAPs) frequency induced by NTR1 perfusion. sAPs frequency was measured at 1 min interval. (b). Representative traces of sAP firing in the same pyramidal
neuron before NTR1 treatment (baseline, (1)), 20 min after 10 mM NTR1 treatment (NTR1, (2)), and 20 min after washout (washout, (3)). (c). NTR1 did
not affect resting membrane potential (upper) or sAPs amplitude (bottom) in pyramidal neurons. n512.
Figure 3 | NTR1 decreases the AP threshold. (a). Representative traces of membrane potential responding to step depolarization by current injection.
Membrane potential was current-clamped at -70 mV; step depolarization was delivered by current injections with amplitudes ranging from 250 pA to
90 pA. (b). Frequency-current relationship of evoked action potential. (c). The percentage of neurons generating action potential by 10 pA current injection.
(d). The percentage of neurons generating action potential by 30 pA current injection. n512. *p , 0.05.
www.nature.com/scientificreports
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difference was observed in mEPSC frequency (Fig. 5a, b) or
amplitude (Fig. 5a, c) after NTR1 application. These findings
suggest that the effect of NTR1 is major at a cellular level instead
of a network based mechanism.
NTR1 rescues the LTP reduction induced by Ab1-42 oligomers.
Changes in membrane excitability are known to be critical for
memory formation34 as the level of excitability within a network can
reflect synaptic efficacy and plasticity32. In addition, Ab elevation was
able to reduce the neuron excitability in vivo and in vitro3,7. Therefore,
we investigated the effects of NTR1 on Ab oligomers-induced
reduction of hippocampal long-term potentiation (LTP), a form of
long-term synaptic plasticity. NTR1 alone didn’t affect LTP in control
condition (222.16 6 18.39% for NTR1 alone versus 228.59 6 10.50%
for vehicle-treated slices) (Fig. 6a, d). Ab1-42 oligomers (200 nM)
perfusion significantly impaired LTP (152.49 6 6.50% versus 228.59
6 10.50% for vehicle-treated slices, p,0.001) (Fig. 6b, d), which are
consistent with previously reports35,36. NTR1 largely rescued the Ab-
induced reduction in LTP (213.19 6 9.36%, p,0.001) (Fig. 6c, d).
Importantly, in the presence of 10 nM TTX which reduces the
spontaneous firing activity, the protective effect of NTR1 against
Ab-induced LTP decline was completely abolished (Fig. 6c, d),
suggesting that the protective effect of NTR1 on LTP is neuronal
excitability-dependent. In our experiments, we did not find
significant difference in basal neuronal synaptic transmission among
all groups (Fig. 6e).
NTR1 rescues learning and memory deficits in an AD mouse
model. Spatial memory measured through the Morris Water Maze
task is likely to be strongly dependent on neural activity in the CA1
sub-region of the hippocampus37,38. Therefore, we studied the effects of
NTR1 on spatial memory in an Ab deposition mouse model expressing
a chimeric human amyloid precursor protein (APP695swe) and a
mutant human presenilin 1 (PS1-dE9) both directed to CNS neurons.
After 4 months of NTR1 administration, the 7-month old animals were
trained with the Morris Water Maze. All animals exhibited significant,
substantial reductions in their times to find the platform over the
training sessions (Fig. 7a). However, there were significant differences
between APP/PS1 mice and WT mice (p 5 0.025). Compared to WT
mice, 7-month old APP/PS1 took significantly longer time to find the
platform occurring from the fourth-training day, implying a significant
impairment of learning and memory. However, there were also
significant differences between APP/PS1 mice treated with vehicle
and those treated with NTR1 (Fig. 7a).
In the probe test, the platform was removed and the animal was
released from the opposite quadrant. During the 60 sec of the probe
trial, the number of crossings of APP/PS1 mice was significant less than
WT control (1.75 6 0.53 versus 5.10 6 0.41, n510, p , 0.001).
However, the number of crossings of the NTR1-treated APP/PS1 mice
(3.33 6 0.33, n 5 8) was significant more than the vehicle-treated
APP/PS1 mice (p 5 0.020) (Fig. 7b, c). In addition, the APP/PS1 mice
spent significant less time in the target quadrant compared to WT mice
(15.86 6 1.99 s versus 30.14 6 1.68, n510, p , 0.001). However, the
NTR1-treated APP/PS1 mice spent longer time in the target quadrant
(24.11 6 2.22, p 5 0.015), which was significant more than vehicle-
treated APP/PS1 mice and similar to WT controls (Fig. 7d). There was
no significant difference in swimming speed among all groups (Fig. 7e).
These data indicate that NTR1 supplementation improves spatial
learning and memory following Ab elevation.
Discussion
The neurodegeneration observed in AD has been associated with
progressive decrease in neuronal activity and synaptic dismant-
Figure 4 | Effect of NTR1 on AP properties and voltage-gated K1 currents in hippocampal neurons. (a). Representative traces of spontaneous action
potential in the same CA1 pyramidal neuron before NTR1 application (baseline), in the presence of NTR1, and 20 min after NTR1 washout. The horizontal
dotted lines represent the threshold and the resting membrane potential. Arrows indicate the negative peaks reached by the AHP. (b). Average
of spike threshold. n59 cells. (c). Average of AHP amplitude, which are measured as the difference between resting membrane potential and
AHP peak. n59 cells. (d). Representative voltage-gated K1 currents were evoked by delivering a voltage step to 150 mV in cells held at 270 mV. (e). K1
current quantification showed a reversible reduction of sustained K1 current in CA1 pyramidal neurons by NTR1 application (n57). Data from the same
neuron were connected by lines. *p , 0.05, **p , 0.01.
www.nature.com/scientificreports
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ling9,10,39. Modulation of intrinsic properties of individual neurons
represents a potential strategy for preventing and/or halting AD
progression. Here, we found an increase in intrinsic excitability of
hippocampal neurons by a natural compound, NTR1. Furthermore,
our study is the first time to show that NTR1 prevented the Ab-
induced synaptic plasticity deficits in brain slices and improved spa-
tial learning and memory in an AD mouse model with a possible
mechanism involving in neuronal excitability modulation.
A progressive decrease in neuronal activity was found in AD
brains9–11 and in mouse dentate gyrus following Ab1–42 oligomers
exposure7. Similarly in a study on 5XFAD mice, bearing five familial
AD transgenes, Ab1-42 production was associated with a reduction
of membrane excitability in hippocampal CA1 pyramidal neurons3.
However, several studies found neuronal hyperexcitability in the
hippocampal-entorhinal cortex network in AD mice6,8,40. Busche
MA and colleges found a redistribution of synaptic drive between
Figure 5 | Effect of NTR1 on mEPSCs in hippocampal neurons. (a). Representative recordings of mEPSCs in pryimdial neurons from acute slices in the
presence or absence of 10 mM NTR1. To isolate excitatory miniature events, 100 mM picrotoxin and 0.5 mM tetrodotoxin were added to the recording
bath solution. (b). Average effect of NTR1 mEPSCs frequency. (c). Average effect of NTR1 on mEPSCs amplitude. n58 cells.
Figure 6 | NTR1 prevents Ab1-42 oligomers-induced hippocampal LTP reduction through a neuronal activity-dependent mechanism. (a). NTR1
alone doesn’t affect LTP. (b). NTR1 rescued oligomeric Ab1-42-induced LTP decline. (c). Pharmacological suppression of spontaneous firing with 10 nM
TTX abolishes the protective effect of NTR1 against oligomeric Ab1-42-induced LTP impairment. Representative traces of fEPSPs before and 60 min after
LTP induction with vehicle (black) or NTR1 treatment (gray) are showed in upper panel. The gray bar indicates Ab1-42 oligomers perfusion for 20 min
before TBS or TTX perfusion during whole recording. (d). Residual potentiation of fEPSPs during the last five minutes of the one hour recording.
(e). Unchanged basal neurotransmission at hippocampal SC-CA1 synapses with indicated treatments. n57–10 slices from 3–5 mice. *** p,0.001; ns, no
significant.
www.nature.com/scientificreports
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silent and hyperactive neurons in AD cortex12, suggesting that a
disturbance in the equilibrium between silent and hyperactive neu-
rons, rather than an overall decrease in synaptic activity, contributes
to the synaptic dysfunction in AD. These findings suggest that modu-
lation of intrinsic properties of individual neurons is a potential
strategy for preventing and/or halting AD progression. In the present
study, we found that NTR1, a saponin isolated from Panax notogin-
seng, increased spontaneous firing rate in hippocampal pyramidal
neurons in a reversible manner without affecting resting membrane
potential or action potential amplitude. Analysis of evoked action
potentials elicited with a depolarizing current injection showed a
lower spike threshold in NTR1-treated pyramidal neurons, suggest-
ing that NTR1 increases the membrane excitability of hippocampal
pyramidal neurons. NTR1 has no significant effect on the maximum
firing rate of hippocampal neurons, in consistent with the effect on
AHP, which is known to be involved in delaying the subsequent
firing of action potentials during high frequency firing41. These find-
ings suggest that NTR1 might have the capacity of increasing neur-
onal excitability without resulting in hyperactivity. This advantage of
NTR1 on modulation of neuronal excitability is very important
because hyperactive neurons with more frequency firing are known
to increase the risk of seizures8,42,43.
In an attempt to investigate mechanisms underlying changes in
excitability, we analyzed the neuronal voltage-gated K1 channels. An
efflux of potassium or influx of chloride can hyperpolarize the cell and
thus inhibit threshold from being reached. Recent research has demon-
strated that changes in voltage-gated K1 channel activity play a major
pathogenetic role in early stages of AD44,45. Several studies have shown
that Ab increased the K1 currents including fast-inactivating K1 cur-
rents (IA) and delayed rectifier K1 currents45,46. In fact, blocking specific
K1 channels has been proposed as a potential strategy for the treatment
of neurodegenerative diseases44,47. Here, we found that NTR1 signifi-
cantly decreased sustained K1 currents in hippocampal neurons from
either brain slice or primary cultures. These results suggest that inhibi-
tion of K1 channel activity may contribute to the decrease of spike
threshold and finally modulate neuronal excitability. However, further
work is needed to investigate the molecular mechanism underlying the
action of NTR1 on specific voltage-gated K1 channel.
Changes in intrinsic neuronal excitability by changing the func-
tion of voltage-gated ion channels can produce broader, persistent
changes in synaptic strength including synaptic transmission and
plasticity48. In recent years, several lines of evidence have indicated
that Ab-induces synaptic dysfunction, in part, through alteration of
neuronal intrinsic excitability or disruption of the modulation of
intrinsic excitability in AD brains48. Soluble Ab oligomers, composed
of dimers, trimers, tetramers and higher order assemblies, inhibit
hippocampal long-term potentiation (LTP), a surrogate cellular
model for memory and learning35,36,49. Interestingly, previous studies
have shown that Ab modulates activity of a suite of ionic conduc-
tances, mostly potassium channels through amylin receptor, which
resulting in aberrant neuronal excitability50,51. In addition, another
independent study showed that Ab -induced depression of hippo-
campal long-term potentiation is associated with the amylin recep-
tor52. These findings suggest that alternation of neuronal excitability
might contribute to Ab-induced LTP impairment. In the present
study, we found that the deteriorating effect of Ab on hippocampal
LTP was significantly suppressed by NTR1, a drug acting onto neur-
onal excitability. However, when spontaneous firing activity was
reduced by a low dose of TTX (10 nM)53, the beneficial effect of
NTR1 on Ab-induced LTP impairment was completely blocked.
Thus it is very likely that the improvement in synaptic plasticity
caused by NTR1 due to the alternation of neuronal excitability.
Figure 7 | NTR1 administration ameliorates memory deficit in APP/PS1 transgenic mice. Morris water maze test were conducted in mice with or without
NTR1 (5 mg kg21 day21, 4 months) treatment. (a). Escape latencies in hidden-platform test. (b). Representative swimming paths during the probe trial. (c).
Numbers of crossings from the previous platform location. (d). Time spent in target quadrant during the probe trial. (e). The swimming speeds of mice were
similar in all groups. *p,0.05, n58–10 mice for each group.
www.nature.com/scientificreports
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LTP is widely considered one of the major cellular mechanisms
underlying learning and memory54. Thus, we further evaluated the
effects of NTR1 on spatial memory in vivo in an Ab-overexpressing
mouse model. Spatial memory is understood to be strongly depend-
ent on neuronal activity in the sub-region of hippocampus38.
Previous studies have indicated that a decrease in membrane excit-
ability induced by Ab affects neuronal activity, and probably con-
tributes to the deficits of learning and memory in AD mouse
models3,7. In the present study, all mice exhibited significant, sub-
stantial reductions in their times to find the hidden platform over the
training sessions in the MWM test. However, the escape latencies of
APP/PS1 mice were significantly delayed compared to the control
group, which suggested that Ab decreased spatial learning ability of
mice. The results from the probe trial showed that the Ab overex-
pressing mice spent less time in the platform quadrant with less
crossing times, which further indicated that AD mice display impair-
ment of the maintenance of established memory. Most importantly,
NTR1 administration for 4 months significantly improved the spatial
learning performance of AD mice both during the hidden phase and
the probe trial of the MWM test, suggesting that this strategy might
be beneficial in the treatment of memory loss in AD.
In summary, our data clearly demonstrate that NTR1, with a
capacity of modulating the excitability of hippocampal pyramidal
neurons, could prevent Ab-induced synaptic dysfunction and
improve hippocampal-based memory performance in an AD mouse
model. Although a previous study showed that NTR1 have protective
effects against cell death induced by Ab1-42 (10uM) and Ab25-35
(20 uM) in cultured PC12 neuronal cells55, our work revealed a novel
mechanism involved in modulation of neuronal excitability, which
plays a critical role in the protective effects of NTR1 against Ab
toxicity.
Methods
Animals. C57BL/6J mice were maintained on a 12 h light/dark cycle in temperature-
and humidity-controlled rooms of the animal facility of Columbia University. Male
mice (3–4 month old) were used for slice preparation and electrophysiological
recording. For behavioral experiments, two-month-old male APP695sw/PS1DE9
C57BL/6J (APP/PS1) mice and C57BL/6J (WT) littermates were purchased from
Institute of Laboratory Animal Sciences, CAMS&PUMC (Beijing, China) and housed
in a standard specific-pathogen-free facility of Beijing Normal University with free
access to water and rodent chow and were kept until the age of three months. APP/
PS1 mice were then randomly divided into 2 groups (n510 mice per group): NTR1
(5 mg kg21 day21, by gavage) treated and vehicle (sterile distilled water) treated
animals. Wild type littermates (n510) treated with vehicle were used as a normal
control. After 4 months of administration, the Morris Water Maze task was carried
out to evaluate memory in mice. All the animal experiments were carried out in
accordance with the guidelines approved by the Institutional Animal Care and Use
Committee of Columbia University and Beijing Normal University, respectively.
Preparation of NTR1 and Ab1-42 oligomers. NTR1 (C47H80O18, molecular
weight 933.16, Fig. 1A), with a purity . 99.0%, was purchased from the Chinese
National Institutes for Food and Drug Control (Being, China). NTR1 was dissolved in
sterile H2O to make 1 mM stock solution and stored at 220uC.
Human Ab1-42 oligomers were prepared from commercially available synthetic
peptides (American Peptide Company, Inc., Sunnyvale, CA) as described56. Briefly,
the lyophilized peptide (1 mg) was resuspended in 250 mL cold 1,1,1,3,3,3-hexa-
fluoro-2-propanol (HFIP, Sigma) and aliquoted in 3 polypropylene vials. After
2 hours of incubation under the hood, HFIP was removed under gentle vacuum to
form a thin film of peptide. Sealed vials were then stored at –20uC. Prior to use,
14.8 mL anhydrous DMSO (Sigma) was added to one sealed vial to obtain a pure
monomeric Ab/DMSO solution that was sonicated for 10 min and then aliquoted by
1.6 mL per vial (5 mM). Oligomeric Ab42 was obtained by incubating an aliquot of
monomeric Ab/DMSO solution in 100 mL sterile PBS or ACSF (80 mM) at 4uC for
24 hours.
Preparation of mouse acute brain slice. Coronal brain sections of 350 mm in
thickness were sectioned in a cold sucrose-based cutting solution containing (in mM):
195 sucrose, 10 NaCl, 25 NaHCO3, 25 glucose, 2.5 KCl, 1.25 NaH2PO4, 2 Na
Pyruvate, 0.5 CaCl2, and 7 MgCl2 (pH 7.3) using a vibratome (Leica VT1000S) as
described in previous studies57,58. Slices were permitted to recover in a submerged
chamber at room temperature for at least 90 min before recordings, perfused with
recording solution containing (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH2PO4, 25
NaHCO3, 2 CaCl2, 1 MgCl2, 25 glucose (pH 7.3) and continuously bubbled with 95%
O2 and 5% CO2.
Whole-cell patch clamp studies. Patch clamp studies in acute brain slices were
performed as previously described57,58. Briefly, for patch-clamp recording in cell
cultures, cover slips were transported from the incubator to the recording chamber in
a cell culture dish containing recording bath solution (in mM): 119 NaCl, 5 KCl, 20
HEPES, 30 glucose, 2 CaCl2, 2 MgCl2. The osmolarity was adjusted to ,330 mOsm
with sucrose and the pH adjusted to 7.3 with 10N NaOH. For patch-clamp recording
in brain slices after recovery, hippocampal CA1 pyramidal neurons were patched
based on their morphology and location. We acquired whole-cell patch clamp
recordings by using a MultiClamp 700B amplifier and Clampex data acquisition
software (Molecular Devices) at room temperature. A glass pipette of 5–8 MV was
fabricated and filled with electrode solution (in mM): 130 Potassium-gluconate, 10
KCl, 5 HEPES, 5 MgCl2, 0.06 CaCl2, 0.6 EGTA, 2 MgATP, 0.2 Na2GTP, and 20
Phosphocreatine. The osmolarity was adjusted to 310 mOsm and the pH adjusted to
7.1 with KOH. Spontaneous action potentials (sAPs) were recorded in current-clamp
mode. Cells were held at 270 mV and step currents from 250 pA to 190 pA at
20 pA intervals were injected to elicit evoked action potentials (eAPs). K1 currents
were recorded in the voltage-clamp mode by delivering a 300 ms voltage step to
50 mV in cells held at 270 mV in the presence of 0.5 mM tetrodotoxin (TTX).
mEPSCs were recorded in the presence of 100 mM picrotoxin and 0.5 mM TTX.
Signals were filtered at 2 kHz, digitized at 10 kHz, stored and analyzed off-line using
Clampfit 10 (Molecular Devices) and MiniAnalysis Software (Synaptosoft Version
6.0.7). In all whole-cell recordings, a hyperpolarizing test pulse was applied at the end
of the recording to ensure that the series resistance did not change significantly and
was less than 25 MV. If so, the recordings were discarded.
Long-term potentiation (LTP) recording. Hippocampal CA1 LTP was recorded as
described previously56. Transverse hippocampal slices (400 mm) were cut from the
mouse brain and maintained in an interface chamber at 29uC and perfused with
artificial cerebrospinal fluid (ACSF) continuously bubbled with 95% O2 and 5% CO2.
The ACSF composition in mM was: 124 NaCl, 4.4 KCl, 1 Na2HPO4, 25 NaHCO3, 2
CaCl2, 2 MgCl2, and 10 glucose. Field-excitatory post-synaptic potentials (fEPSPs)
were recorded from the CA1 region of the hippocampus by placing the stimulating
electrode at the level of the Schaeffer collateral fibers, whereas the recording electrode
was placed in the CA1 stratum radiatum. Extracellular responses were acquired using
Clampex Software 10.2 (Molecular Device) and a microamplifier (IE-210, Warner
Instruments). Basal synaptic transmission (BST) was assayed by plotting the stimulus
voltage (V) against slopes of fEPSP to generate input-output relations. For LTP
experiments, a test pulse was applied every minute at an intensity that evokes a
response ,35% of the maximum evoked response. LTP was induced by h-burst
stimulation (4 pulses at 100 Hz, with the bursts repeated at 5 Hz and each tetanus
including 3 ten-burst trains separated by 15 sec). Responses were recorded for
2 hours after tetanization and measured as fEPSP slope expressed as percentage of
baseline. Residual potentiation was calculated by averaging the fEPSP slopes
occurring over the last five minutes of the recording.
Behavioral studies. Spatial learning and memory were evaluated using the Morris
water maze as previously described59. Briefly, in the hidden platform test, a platform
was placed at the center of one quadrant and submerged 1 cm below the water level.
Mice were given 2 trials per day for 8 consecutive days (day1–8). During each trial,
mice were released from four semi-randomly assigned starting points and allowed to
swim for 90 s. After mounting the platform, the escape latency was recorded by
software. If a mouse failed to reach the platform within 90 s, it was guided to the
platform. In both situation, the animals were allowed to rest on the platform for
15 sec., and were then placed in the home cage. On the day following the hidden
platform test (day 9), the probe trial was performed with the platform removed. The
animal was released from the opposite quadrant and allowed to swim freely for 60 s.
The time spent in the target quadrant, where the platform had been located during
training, and the number of platform crossing were measured. All experiments were
conducted at approximately the same time of each day. Investigators were blind of
mouse genotypes and treatments until the behavioral tests were finished.
Statistics. Data shown in the figures represent mean 6 s.e.m. Student’s paired t-tests
were used in all the experiments where the effect of NTR1 was tested in the same cell.
Independent t-tests were used to compare different populations of cell, synapses or
mouse. For comparison of firing frequency in current injection experiment, repeat-
measures ANOVA was used. For comparison of LTP and escape lantency in Morris
Water Maze test, two-way ANOVA was used. Significance was accepted at p , 0.05.
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